Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 675

1.

Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.

Osman N, Mesplède T, Oliveira M, Hassounah S, Wainberg MA, Brenner BG.

AIDS. 2018 Aug 24;32(13):1773-1780. doi: 10.1097/QAD.0000000000001903.

PMID:
29894388
2.

The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.

Pham HT, Labrie L, Wijting IEA, Hassounah S, Lok KY, Portna I, Goring ME, Han Y, Lungu C, van der Ende ME, Brenner BG, Boucher CA, Rijnders BJA, van Kampen JJA, Mesplède T, Wainberg MA.

J Infect Dis. 2018 Jul 24;218(5):698-706. doi: 10.1093/infdis/jiy175.

PMID:
29617824
3.

Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A.

Tietjen I, Williams DE, Read S, Kuang XT, Mwimanzi P, Wilhelm E, Markle T, Kinloch NN, Naphen CN, Tenney K, Mesplède T, Wainberg MA, Crews P, Bell B, Andersen RJ, Brumme ZL, Brockman MA.

Antiviral Res. 2018 Apr;152:94-103. doi: 10.1016/j.antiviral.2018.02.017. Epub 2018 Feb 22.

PMID:
29476895
4.

The antimalarial drug amodiaquine possesses anti-ZIKA virus activities.

Han Y, Mesplède T, Xu H, Quan Y, Wainberg MA.

J Med Virol. 2018 May;90(5):796-802. doi: 10.1002/jmv.25031. Epub 2018 Feb 21.

PMID:
29315671
5.

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.

Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Cheneau C, Beck-Wirth G, Faller JP, Mohseni-Zadeh M, Martinot M, Wainberg MA, Fafi-Kremer S.

J Antimicrob Chemother. 2018 Apr 1;73(4):1045-1053. doi: 10.1093/jac/dkx475.

PMID:
29244129
6.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

7.

Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.

Asahchop EL, Meziane O, Mamik MK, Chan WF, Branton WG, Resch L, Gill MJ, Haddad E, Guimond JV, Wainberg MA, Baker GB, Cohen EA, Power C.

Retrovirology. 2017 Oct 16;14(1):47. doi: 10.1186/s12977-017-0370-5.

8.

Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference.

Sze A, Olagnier D, Hadj SB, Han X, Tian XH, Xu HT, Yang L, Shi Q, Wang P, Wainberg MA, Wu JH, Lin R.

Viruses. 2017 Oct 3;9(10). pii: E287. doi: 10.3390/v9100287.

9.

M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.

Oliveira M, Brenner BG, Xu H, Ibanescu RI, Mesplède T, Wainberg MA.

J Antimicrob Chemother. 2017 Nov 1;72(11):3008-3011. doi: 10.1093/jac/dkx280.

PMID:
28961903
10.

Investigational HIV integrase inhibitors in phase I and phase II clinical trials.

Han Y, Mesplède T, Wainberg MA.

Expert Opin Investig Drugs. 2017 Nov;26(11):1207-1213. doi: 10.1080/13543784.2017.1378643. Epub 2017 Sep 28. Review.

PMID:
28956664
11.

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Hassounah SA, Alikhani A, Oliveira M, Bharaj S, Ibanescu RI, Osman N, Xu HT, Brenner BG, Mesplède T, Wainberg MA.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01695-17. doi: 10.1128/AAC.01695-17. Print 2017 Dec.

12.

HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity.

Anstett K, Brenner B, Mesplède T, Wainberg MA.

J Virol. 2017 Oct 13;91(21). pii: e00912-17. doi: 10.1128/JVI.00912-17. Print 2017 Nov 1.

13.

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23.

PMID:
28747274
14.

Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication.

Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA.

Sci Rep. 2017 Jul 24;7(1):6345. doi: 10.1038/s41598-017-06612-2.

15.

Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.

Heredia A, Hassounah S, Medina-Moreno S, Zapata JC, Le NM, Han Y, Foulke JS Jr, Davis C, Bryant J, Redfield RR, Wainberg MA.

J Antimicrob Chemother. 2017 Sep 1;72(9):2570-2573. doi: 10.1093/jac/dkx195.

PMID:
28637235
16.

HIV drug resistance against strand transfer integrase inhibitors.

Anstett K, Brenner B, Mesplede T, Wainberg MA.

Retrovirology. 2017 Jun 5;14(1):36. doi: 10.1186/s12977-017-0360-7. Review.

17.

A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.

Sanche S, Sheehan N, Mesplède T, Wainberg MA, Li J, Nekka F.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):469-476. doi: 10.1002/psp4.12200. Epub 2017 May 27.

18.

HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.

Brenner BG, Ibanescu RI, Oliveira M, Roger M, Hardy I, Routy JP, Kyeyune F, Quiñones-Mateu ME, Wainberg MA; Montreal PHI Cohort Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2171-2183. doi: 10.1093/jac/dkx118.

PMID:
28472323
19.

Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.

Melnychuk L, Ajamian L, Jean-Pierre P, Liang J, Gheorghe R, Wainberg MA, Zaharatos GJ.

Vaccine. 2017 May 9;35(20):2736-2744. doi: 10.1016/j.vaccine.2017.03.039. Epub 2017 Apr 6.

PMID:
28392143
20.

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.

Mesplède T, Leng J, Pham HT, Liang J, Quan Y, Han Y, Wainberg MA.

MBio. 2017 Apr 4;8(2). pii: e00157-17. doi: 10.1128/mBio.00157-17.

21.

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.

Quan Y, Xu H, Han Y, Mesplède T, Wainberg MA.

J Virol. 2017 Apr 13;91(9). pii: e00075-17. doi: 10.1128/JVI.00075-17. Print 2017 May 1.

22.

Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study.

Palanisamy N, Osman N, Ohnona F, Xu HT, Brenner B, Mesplède T, Wainberg MA.

AIDS Res Ther. 2017 Jan 7;14(1):2. doi: 10.1186/s12981-016-0130-y.

23.

Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors.

Xu HT, Hassounah SA, Colby-Germinario SP, Oliveira M, Fogarty C, Quan Y, Han Y, Golubkov O, Ibanescu I, Brenner B, Stranix BR, Wainberg MA.

J Antimicrob Chemother. 2017 Mar 1;72(3):727-734. doi: 10.1093/jac/dkw514.

24.

Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec.

Brenner BG, Ibanescu RI, Hardy I, Stephens D, Otis J, Moodie E, Grossman Z, Vandamme AM, Roger M, Wainberg MA; and the Montreal PHI, SPOT cohorts.

AIDS. 2017 Mar 13;31(5):707-717. doi: 10.1097/QAD.0000000000001383.

PMID:
28005684
25.

HIV and Zika: When will we be able to end these epidemics?

Wainberg MA, Lever AM.

Retrovirology. 2016 Nov 15;13(1):80. No abstract available.

26.

Achieving the 90-90-90 target: incentives for HIV testing.

Wainberg MA, Hull MW, Girard PM, Montaner JSG.

Lancet Infect Dis. 2016 Nov;16(11):1215-1216. doi: 10.1016/S1473-3099(16)30383-8. No abstract available.

PMID:
27788971
27.

We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance.

Brenner B, Wainberg MA.

AIDS. 2016 Nov 13;30(17):2725-2727. No abstract available.

PMID:
27782967
28.

Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay.

Han YS, Penthala NR, Oliveira M, Mesplède T, Xu H, Quan Y, Crooks PA, Wainberg MA.

J Med Virol. 2017 Mar;89(3):397-407. doi: 10.1002/jmv.24660. Epub 2016 Aug 22.

PMID:
27509184
29.

Antibody-Dependent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers.

Isitman G, Lisovsky I, Tremblay-McLean A, Kovacs C, Harris M, Routy JP, Bruneau J, Wainberg MA, Tremblay C, Bernard NF.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1079-1088. Epub 2016 Sep 7.

PMID:
27499379
30.

Will LEDGIN molecules be able to play a role in a cure for HIV infection?

Mesplède T, Wainberg MA.

EBioMedicine. 2016 Jun;8:14-15. doi: 10.1016/j.ebiom.2016.05.007. Epub 2016 May 7. No abstract available.

31.

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.

Brenner BG, Wainberg MA.

Virus Res. 2017 Jul 15;239:1-9. doi: 10.1016/j.virusres.2016.07.006. Epub 2016 Jul 12. Review.

PMID:
27422477
32.

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.

Oliveira M, Ibanescu RI, Pham HT, Brenner B, Mesplède T, Wainberg MA.

AIDS. 2016 Sep 24;30(15):2267-73. doi: 10.1097/QAD.0000000000001191.

PMID:
27367488
33.

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.

Han YS, Mesplède T, Wainberg MA.

Infect Genet Evol. 2016 Dec;46:286-291. doi: 10.1016/j.meegid.2016.06.047. Epub 2016 Jun 25. Review.

PMID:
27353185
34.

CRISPR/Cas9: a double-edged sword when used to combat HIV infection.

Liang C, Wainberg MA, Das AT, Berkhout B.

Retrovirology. 2016 May 27;13(1):37. doi: 10.1186/s12977-016-0270-0. No abstract available.

35.

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.

Pham HT, Mesplède T, Wainberg MA.

Retrovirology. 2016 Apr 30;13(1):31. doi: 10.1186/s12977-016-0265-x.

36.

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.

Anstett K, Cutillas V, Fusco R, Mesplède T, Wainberg MA.

J Antimicrob Chemother. 2016 Aug;71(8):2083-8. doi: 10.1093/jac/dkw109. Epub 2016 Apr 15.

37.

CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S, Wainberg MA, Liang C.

Cell Rep. 2016 Apr 19;15(3):481-489. doi: 10.1016/j.celrep.2016.03.042. Epub 2016 Apr 7.

38.

Might dolutegravir be part of a functional cure for HIV?

Wainberg MA, Han YS, Mesplède T.

Can J Microbiol. 2016 May;62(5):375-82. doi: 10.1139/cjm-2015-0725. Epub 2016 Jan 27. Review.

39.

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.

Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplède T, Golubkov O, Roger M, Garcia F, Martinez E, Wainberg MA.

J Antimicrob Chemother. 2016 Jul;71(7):1948-53. doi: 10.1093/jac/dkw071. Epub 2016 Mar 29.

40.

Early HIV treatment to forestall drug resistance.

Wainberg MA.

Lancet Infect Dis. 2016 May;16(5):512-513. doi: 10.1016/S1473-3099(16)00013-X. Epub 2016 Jan 29. No abstract available.

41.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

42.

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy.

Wainberg MA, Mesplede T.

J Int AIDS Soc. 2015 Dec 4;18:20824. doi: 10.7448/IAS.18.1.20824. eCollection 2015. No abstract available.

43.

Flueggether A and Virosinine A, Anti-HIV Alkaloids from Flueggea virosa.

Zhang H, Zhu KK, Han YS, Luo C, Wainberg MA, Yue JM.

Org Lett. 2015 Dec 18;17(24):6274-7. doi: 10.1021/acs.orglett.5b03320. Epub 2015 Dec 3.

PMID:
26632657
44.

Has the world ceased to care about HIV? And what can we do about it?

Wainberg MA, Kippax S, Bras M, Sow PS.

J Int AIDS Soc. 2015 Dec 1;18:20818. doi: 10.7448/IAS.18.1.20818. eCollection 2015. No abstract available.

45.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group.

N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.

46.

Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase.

Xu HT, Colby-Germinario SP, Hassounah S, Quashie PK, Han Y, Oliveira M, Stranix BR, Wainberg MA.

Antimicrob Agents Chemother. 2015 Nov 16;60(1):600-8. doi: 10.1128/AAC.02203-15. Print 2016 Jan.

47.

Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.

Sluis-Cremer N, Wainberg MA, Schinazi RF.

Future Microbiol. 2015;10(11):1773-82. doi: 10.2217/fmb.15.106. Epub 2015 Oct 30. Review.

48.

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, Sandstrom PA, Mesplède T, Wainberg MA.

J Virol. 2015 Dec;89(23):12002-13. doi: 10.1128/JVI.02131-15. Epub 2015 Sep 16.

49.

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.

Oliveira M, Mesplède T, Moïsi D, Ibanescu RI, Brenner B, Wainberg MA.

AIDS. 2015 Nov;29(17):2255-60. doi: 10.1097/QAD.0000000000000866.

PMID:
26372484
50.

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA.

J Virol. 2015 Nov;89(22):11269-74. doi: 10.1128/JVI.01881-15. Epub 2015 Aug 26.

Supplemental Content

Loading ...
Support Center